Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

For MedTech founders and regulatory leaders, the difference between a credible first‑in‑human (FIH) plan and an expensive science project often comes down to one question: when will we be cleared to start? In Latin America, Brazil is increasingly attractive because the regulatory environment is becoming more predictable for sponsors who prepare correctly. The biggest practical shift is that Brazil’s current framework is designed around a defined review window for ANVISA’s assessment of primary clinical‑trial petitions.

This article translates that “clock” into a sponsor-ready activation timeline—what to do first, what can run in parallel, and where teams still lose weeks. It is written for early-stage device companies planning a first-in-human or very early feasibility study and aiming to use Brazil’s speed without compromising compliance.

1) What the “ANVISA clock” changes (and what it does not)

A defined review window is only valuable if your submission is complete and internally consistent. In practice, teams still face delays from avoidable dossier defects, mismatched translations, missing proof of manufacturer authorization, or unclear risk management documentation.

• What changes: Sponsors can build a tighter critical path because the regulatory review is no longer an open-ended variable.
• What does not change: Poor dossier quality, unclear clinical rationale, and weak local operational readiness can still extend the activation timeline.

Think of the “90-day clock” as a predictability multiplier. It rewards teams that treat activation as a program, not a document handoff.

2) A sponsor-ready activation timeline for FIH MedTech studies in Brazil

Below is a practical timeline for a single-country Brazil activation that is common for early-stage MedTech programs. Actual sequencing depends on device risk classification, study design, and whether you already have an audited quality system and finalized manufacturing documentation.

Phase A (Weeks 0–2): Define your regulatory “story” and activation plan

Before drafting anything, align internal stakeholders on four elements:

• Clinical intent: What data must your FIH generate (safety, usability, performance, feasibility) to unlock your next milestone?
• Risk position: A simple, defensible summary of hazards, mitigations, and residual risk.
• Operational model: Which hospitals, investigators, and vendor partners can execute within your required timeline?
• Regulatory endpoints: Which approvals are required (ethics, ANVISA, contracts, importation readiness) and what is the critical path?

Common failure mode: Teams finalize the protocol without deciding how the device will be imported, stored, serviced, and returned—creating late-stage amendments and logistics rework.

Phase B (Weeks 2–6): Build the dossier as an integrated package

FIH dossiers fail not because the science is wrong, but because the package is incoherent. Aim to produce a “single narrative” across these documents:

• Protocol + investigator materials: Clear objectives, endpoints, and monitoring plan.
• Device technical file excerpts: What the device is, how it works, and how it is controlled.
• Risk management + usability: Evidence that use-related risks are addressed in training, labeling, and design controls.
• Manufacturing and quality evidence: Enough to support safety and traceability expectations.
• Clinical rationale: Why FIH is appropriate now and why Brazil’s sites can execute safely.

Best practice: Maintain a “regulatory crosswalk” table mapping each claim in the protocol (device description, intended use, risk controls) to supporting evidence in the technical file. This prevents contradictions that trigger regulator questions.

Phase C (Weeks 4–8): Ethics readiness and site operational lock

While the dossier is being finalized, lock down the operational prerequisites that routinely delay activation:

• Site feasibility confirmation: Not generic interest—confirmed equipment compatibility, OR slots, and patient flow.
• Contracts and budget: Early alignment with hospital administration avoids last-minute legal stalls.
• Training plan: How will you prove investigator training and competency for first uses?
• Device logistics: Importation responsibilities, packaging validation, and field support processes.

FIH timelines improve when ethics, contracts, and logistics are treated as first-class workstreams—not “post-approval tasks.”

Phase D (Weeks 8–20): Regulatory review window and question management

Once submitted, your main objective is to minimize cycles. Even with a defined review window, questions can reset practical timelines. Sponsors can reduce rework by planning for:

• Rapid response capability: A named owner who can coordinate answers across engineering, QA/RA, and clinical.
• Document control discipline: Consistent versioning, translation control, and traceability of edits.
• Pre-drafted evidence packets: Sterilization summary, labeling package, risk management summary, device master record excerpts.

Tip: When responding to questions, avoid “new storylines.” Keep answers anchored to the original intended use and risk position unless a formal amendment is required.

3) Where FIH teams still lose time in Brazil

Even with improved predictability, sponsors still lose weeks in three recurring areas:

• Under-scoped translations: Technical and clinical translations require domain expertise, not generic language services.
• Unclear importer/registration model: If responsibilities for importation and regulatory representation are not defined, device availability becomes the bottleneck.
• Late site readiness: Contracts, budgets, and first-case scheduling often lag behind the regulatory path.

The fix is not “work faster.” The fix is to design an activation system where regulatory, quality, and operations are integrated from day one.

4) A practical checklist before you start your FIH activation

• Have we defined the minimum FIH dataset required for our next financing or partnership step?
• Is our intended use and risk position consistent across protocol, device description, and labeling?
• Do we have a locked plan for importation, storage, servicing, and returns?
• Are our sites contract-ready with budgets aligned and first-case logistics mapped?
• Do we have a “rapid response” team prepared for regulator questions?

FAQ: Brazil first‑in‑human MedTech study activation

1) Can a defined review window guarantee my exact start date?

No. It improves predictability, but start dates still depend on dossier quality, question cycles, ethics timing, contracts, and logistics.

2) What is the most common avoidable delay for early-stage sponsors?

Incoherent documentation—contradictions between protocol claims and device evidence, plus weak translation and version control.

3) Should we activate Brazil as a stand-alone FIH or part of a multi-country plan?

Many MedTech startups start with a focused single-country activation to generate clean early human data quickly, then expand once operational learning is captured.

Conclusion: Brazil’s evolving framework can give FIH sponsors a more predictable regulatory path—but only if you build a dossier and activation plan that is operationally executable. Treat the “ANVISA clock” as a program milestone, not a date, and you can turn regulatory predictability into faster, safer first-in-human learning.